Homoharringtonine for the treatment of chronic myelogenous leukemia (Q37123425)

18 August 2017

1 reference

title

Homoharringtonine for the treatment of chronic myelogenous leukemia (English)

1 reference

18 August 2017

1 reference

2

Jorge Cortes

1 reference

18 August 2017

Alfonso Quintás-Cardama

series ordinal

1

1 reference

PubMed ID

18377344

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

6

1 reference

18 August 2017

1029-1037

1 reference

Homoharringtonine: history, current research, and future direction

18 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Inhibition of Translation in Eukaryotic Systems by Harringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Cytotoxicity and cell cycle specificity of homoharringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Homoharringtonine induces apoptosis and growth arrest in human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Molecular modes of action of artesunate in tumor cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.1029

10.1517/14656566.9.6.1029

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18377344